KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Liabilities: 2009-2024

Historic Total Liabilities for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $4.2 billion.

  • Alnylam Pharmaceuticals' Total Liabilities rose 10.67% to $4.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year increase of 10.67%. This contributed to the annual value of $4.2 billion for FY2024, which is 3.02% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Total Liabilities stood at $4.2 billion for FY2024, which was up 3.02% from $4.1 billion recorded in FY2023.
  • Alnylam Pharmaceuticals' 5-year Total Liabilities high stood at $4.2 billion for FY2024, and its period low was $2.4 billion during FY2020.
  • Over the past 3 years, Alnylam Pharmaceuticals' median Total Liabilities value was $4.1 billion (recorded in 2023), while the average stood at $4.0 billion.
  • Data for Alnylam Pharmaceuticals' Total Liabilities shows a peak YoY soared of 149.97% (in 2020) over the last 5 years.
  • Over the past 5 years, Alnylam Pharmaceuticals' Total Liabilities (Yearly) stood at $2.4 billion in 2020, then increased by 27.78% to $3.1 billion in 2021, then grew by 21.26% to $3.7 billion in 2022, then climbed by 9.34% to $4.1 billion in 2023, then increased by 3.02% to $4.2 billion in 2024.